Q3 2025 Novozymes A/S Earnings Call Transcript
Key Points
- Novonesis (Novozymes) B (NVZMF) reported an 8% organic sales growth in the first nine months of 2025, with a strong third quarter performance.
- Emerging markets showed robust growth at 12%, driven by increased local presence and tailored solutions.
- The integration of the Feed Enzyme Alliance acquisition is progressing well, contributing positively to the company's performance.
- The company launched 19 new Biosolutions in 2025, enhancing its product portfolio and market reach.
- Adjusted EBITDA margin increased to 37.3%, reflecting strong operational performance despite currency headwinds.
- The exit from certain countries negatively impacted organic sales growth by around 1 percentage point in the first nine months and 2 percentage points in the third quarter.
- Currency headwinds posed a significant challenge, impacting the adjusted EBITDA margin by around 1 percentage point.
- The Beverage segment experienced a decline due to lower end market volumes.
- Sales growth in developed markets was slower compared to emerging markets, with developed markets growing at 6%.
- The adjusted EBITDA margin is expected to be at the lower end of the 37% to 38% range, indicating pressure from external factors like currency fluctuations.
Ladies and gentlemen, welcome to the Novonesis Interim Report for the first nine months of 2025 conference call. I'm Lorenzo, the Chorus Call operator. (Operator Instructions) And the conference is being recorded. (Operator Instructions) The conference must not be recorded for publication or broadcast. At this time, it's my pleasure to hand over to Tobias Cornelius Björklund. Please go ahead.
/-
Thank you, operator, and welcome, everyone, to the Novonesis conference call for the first nine months of 2025. As mentioned, my name is Tobias Björklund. I'm heading up Investor Relations here at Novonesis. In this call, our CEO, Ester Baiget, and our CFO, Rainer Lehmann, will review our performance for the first nine months of the year as well as the outlook for 2025. Attending today's call, we also have Tina Fano, EVP of Planetary Health Biosolutions; Henrik Joerck Nielsen, EVP of Human Health Biosolutions; Andrew Taylor, EVP of Food & Health Biosolutions; and Claus Crone
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
